Nabitan

Drug Profile

Nabitan

Alternative Names: HGP 4; SP 106

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator HG Pars
  • Class Analgesics; Antiemetics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Nausea and vomiting; Pain

Most Recent Events

  • 08 Jun 2001 Profile reviewed but no significant changes made
  • 03 Feb 1997 No-Development-Reported for Emesis in USA (PO)
  • 03 Feb 1997 No-Development-Reported for Pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top